Riskpilot← Back to searchSign inGet full accessEFFIX PHARMA AS
ASActiveOrg 992559055Tangen 10, 4072 RandabergResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20080 employeeswww.effix-pharma.com
Revenue 2024
NOK 0
EBITDA margin
—
+5% vs 2023
Equity ratio
-588897.7%
Financial strength
Net profit 2024
NOK -10K
-10% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -9K | +5% |
| Net profit | NOK -10K | -10% |
| Total assets | NOK 692 | +518% |
| Equity | NOK -4,1M | +0% |
| Employees | 0 | — |
Legal name
EFFIX PHARMA AS
Org number
992559055
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
21. april 2008
Share capital
NOK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Å utvikle medisiner og kosttilskudd, samt delta som eier i selskaper som driver med tilsvarende virksomhet.
Address
Tangen 10, 4072 Randaberg
Website
www.effix-pharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −4 127 | −2 759 | −978 | −304 | −41 | −230 | −145 | −90 | −173 | −172 | −15 | −16 | −4 | −5 | −3 | −9 | −9 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | −4 127 | −2 759 | −978 | −304 | −41 | −230 | −145 | −90 | −173 | −172 | −15 | −16 | −4 | −5 | −3 | −9 | −9 |
| Net financials | −1 047 | 1 | 0 | −136 | −0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −6 | 0 | 0 | 0 | −1 |
| Profit before tax | −5 174 | −2 758 | −977 | −441 | −42 | −230 | −145 | −90 | −173 | −172 | −15 | −16 | −10 | −5 | −3 | −9 | −10 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −5 174 | −2 758 | −977 | −441 | −42 | −230 | −145 | −90 | −173 | −172 | −15 | −16 | −10 | −5 | −3 | −9 | −10 |
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 43 | 42 | 42 | 17 | 5 | 4 | 4 | 4 | 4 | 4 | 4 | 2 | 2 | 1 | 4 | 0 | 1 |
| Equity | −5 072 | −1 738 | −2 715 | −3 156 | −3 198 | −3 427 | −3 572 | −3 662 | −3 836 | −4 007 | −4 022 | −4 039 | −4 048 | −4 054 | −4 056 | −4 065 | −4 075 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 418 | 3 428 | 3 428 | 3 430 | 3 430 | 3 430 |
| Short-term debt | 5 115 | 1 780 | 0 | 3 172 | 3 203 | 3 432 | 3 576 | 3 667 | 3 840 | 4 012 | 4 027 | 622 | 622 | 626 | 630 | 635 | 646 |
| Total debt | 5 115 | 1 780 | 2 757 | 3 172 | 3 203 | 3 432 | 3 576 | 3 667 | 3 840 | 4 012 | 4 027 | 4 040 | 4 050 | 4 054 | 4 060 | 4 065 | 4 076 |
EBITDA margin
-855800.0%
This company
15.8%
Market median
-5416556% vs market
20082024
Equity ratio
-588897.7%
This company
38.2%
Market median
-1541717% vs market
20082024
Return on equity
-991500.0%
This company
18.4%
Market median
-5388687% vs market
20082024
Net profit margin
-991500.0%
This company
8.1%
Market median
-12240841% vs market
20082024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20082024
Debt / equity
1.00×
This company
0.62×
Market median
-61% vs market
20082024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-01-01 – 2010-12-31
- Annual report 2009Filed via Brønnøysundsregistrene · Period 2009-01-01 – 2009-12-31
- Annual report 2008Filed via Brønnøysundsregistrene · Period 2008-01-01 – 2008-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JM Deputy Member | Deputy Member | 2010 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2010 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Captrol As | Company | 100.0% | 100.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Captrol As
EFFIX PHARMA AS Board members of EFFIX PHARMA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jan Martin Wennesland | Deputy Member | 0 companies |
| Jostein Kåre Kjerstad | Chairman | 0 companies |